Abstract

Rivaroxaban drug used in acute coronary syndrome (ACS), Prevention of cardiovascular death, myocardial infarction and stent thrombosis. Rivaroxaban is a potent selective oral direct factor Xa inhibitor, Rivaroxaban BCS Class II. Depending on the choice of excipient(s) and formulation techniques, it is possible to obtain a variety of systems including physical mixtures, liquid/solid solutions, solid dispersions, and Self-Micro or Self-Nano Emulsifying Drug Delivery Systems (SMEDDS/SNEDDS).Lipid based formulations including lipid solid dispersion formulations offer the potential for enhancing the dissolution and absorption of poorly soluble and/or poorly permeable compounds. Lipid solid dispersions are prepared by three different techniques Solvent evaporation, Hot melt granulation and Spray drying method and evaluated by drug content, saturation solubility, particle size analysis and in-vitro dissolution. Comparative evaluation of three different techniques studied and Spray drying method (SDRD8) shows better dissolution profile as comparative to the other two techniques and marketed market product. Spray dried formulation was stable at accelerated condition.